2020
DOI: 10.1002/cti2.1192
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objective. Coronavirus disease 2019 (COVID-19) outbreak is a major challenge all over the world, without acknowledged treatment. Intravenous immunoglobulin (IVIG) has been recommended to treat critical coronavirus disease 2019 (COVID-19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID-19 patients was lacking. Methods. 325 patients with laboratory-confirmed critical COVID-19 were enrolled from 4 government-designated COVID-19 treatment centres in southern China from December … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
103
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 106 publications
(106 citation statements)
references
References 32 publications
2
103
0
1
Order By: Relevance
“…Other approaches are coming from pooled plasma of healthy donors, and intravenous immunoglobulin (IVIG) which represent one of the most widely diffused immunotherapies in many inflammatory diseases [ 54 ]. Some preliminary studies indicate that IVIG may be useful also during COVID-19 [ 55 , 56 ]; however, it is needed a randomized clinical trial with a large number of patients to verify the effectiveness of this therapy. Other therapeutic options would be to use convalescent plasma, intravenous hyperimmune globulin or neutralizing monoclonal antibodies ( Table 3 ).…”
Section: Insights On Immune-based Therapies For Covid-19mentioning
confidence: 99%
“…Other approaches are coming from pooled plasma of healthy donors, and intravenous immunoglobulin (IVIG) which represent one of the most widely diffused immunotherapies in many inflammatory diseases [ 54 ]. Some preliminary studies indicate that IVIG may be useful also during COVID-19 [ 55 , 56 ]; however, it is needed a randomized clinical trial with a large number of patients to verify the effectiveness of this therapy. Other therapeutic options would be to use convalescent plasma, intravenous hyperimmune globulin or neutralizing monoclonal antibodies ( Table 3 ).…”
Section: Insights On Immune-based Therapies For Covid-19mentioning
confidence: 99%
“…Herein, we are discussing an unsophisticated course of COVID-19 pneumonia in a patient with XLA and its interlaced lines and supportive management. This case suggests that IVIG could be used for treating critically ill patients with COVID-19, particularly at early administration [ 7 ].…”
Section: Discussionmentioning
confidence: 99%
“…Although retrospective, data from Shao et al . included large number of COVID‐19 patients compared to other studies, and hence, data are more reliable 5 . Importantly, a retrospective study of Xie et al 9 .…”
Section: Ivig Immunotherapy For the Treatment Of Covid‐19mentioning
confidence: 96%
“…In a recent article published in Clinical & Translational Immunology , Shao et al 5 . presented a multicentre retrospective cohort study evaluating the efficacy of IVIG in 325 severe and critically ill COVID‐19 patients admitted to hospitals in southern China between December 2019 and March 2020.…”
Section: Ivig Immunotherapy For the Treatment Of Covid‐19mentioning
confidence: 99%
See 1 more Smart Citation